健脾生血片治疗急性缺血性脑卒中合并缺铁性贫血患者的临床观察
- 格式:docx
- 大小:636.00 KB
- 文档页数:10
健脾生血片与多糖铁复合物胶囊治疗妊娠期缺铁性贫血的临床对比研究作者:何丽高江河赵刚来源:《世界中医药》2017年第02期摘要目的:对比观察健脾生血片和多糖铁复合物胶囊治疗妊娠期缺铁性贫血的临床疗效,为临床治疗IDA提供依据。
方法:将200例缺铁性贫血的孕妇随机分为对照组(多糖铁复合物胶囊组)和观察组(健脾生血片组)。
对照组100例,给予多糖铁复合物胶囊治疗;观察组100例,给予健脾生血片口服治疗。
2组患者均于连续治疗1个月,2个月,3个月后,按贫血严重程度,分别分两层观察患者的红细胞计数(RBC)、血红蛋白(Hb)以及血清铁蛋白(SF)的含量变化,计算临床疗效,记录不良反应。
结果:2组治疗3个月后RBC、Hb和SFI均显著改善(P0.05)。
结论:健脾生血片治疗妊娠期贫血起效快、有效率高,不良反应少,值得临床推广应用。
关键词健脾生血片;与多糖铁复合物胶囊;妊娠期缺铁性贫血;临床疗效Abstract Objective:To compare the clinical efficacy of Jianpi Shengxue tablet and iron polysaccharide complex capsules in the treatment of gestational iron deficiency anemia,and provide scientific basis for the treatment of gestational iron deficiency anemia.Methods:A total of 200 gestational iron deficiency anemia patients treated in our hospital were selected and divided into control group (group of iron polysaccharide complex capsules) and observation group (group of Jianpi Shengxue tablet) with 100 cases in each.Patients in the control group were given iron polysaccharide complex capsules,while patients in the observation group were given Jianpi Shengxue tablet.Changes of patients′ RBC,Hb and SF were observed after continuous treatment for one month,two months and three months according to the severity of anemia.Besides,clinical efficacy and adverse reactions were recorded.Results:After three months of treatment,RBC,Hb and SF in two groups were all significantly improved (PKey Words Jianpi Shengxue tablet; Iron polysaccharide complex capsules; Gestational iron deficiencyanemia; Clinical efficacy comparative中图分类号:R242;R556文献标识码:Adoi:10.3969/j.issn.1673-7202.2017.02.024妊娠期缺铁性贫血(Iron-deficiency Anemia,IDA)是妊娠期妇女常见的营养缺乏性疾病,据报道,我国妊娠期妇女贫血的总发生率大于20%,其中IDA占95%[1]。
健脾生血颗粒(片)治疗各型贫血作用解析作者:赵刚张雪琼裴学军肖飞任霞吴木琴来源:《世界中医药》2017年第02期摘要通过健脾生血颗粒(片)对缺铁性贫血、骨髓抑制性贫血、肾性贫血模型动物治疗作用研究结果的分析,并结合其处方特点及相应中医理论,解析健脾生血颗粒治疗各型贫血的作用依据,为该产品更深入的研究方向选择以及临床应用提供参考。
关键词健脾生血颗粒;缺铁性贫血;骨髓抑制性贫血;肾性贫血Abstract The mechanism of Jianpi Shengxue granule in treating various types of anemia was analyzed through research results of the effect of Jianpi Shengxue granule on iron-deficiency anemia,myelopathic anemia,and renal anemia.The characteristics of prescription of this product and its corresponding traditional Chinese medicine theory were also concerned in this article,which may provide as a reference for further research direction and clinical application.Key Words Jianpi Shengxue granules; Iron-deficiency anemia; Myelopathic anemia; Renal anemia中图分类号:R242;R556文献标识码:Adoi:10.3969/j.issn.1673-7202.2017.02.058健脾生血颗粒和健脾生血片是健民药业集团股份有限公司独家生产的中药制剂,二者仅有剂型差别,处方一致,主要成分为党参、茯苓、黄芪、山药、鸡内金、龟甲、大枣等中药成分及营养补充剂硫酸亚铁。
基金项目:中国人口福利基金会妇幼关爱基金———科研支撑计划项目(FY201713254070)作者简介:梅莎莎(1986 11—),女,硕士研究生,主治医师,研究方向:糖尿病肾病的发病机制及中医治疗,E mail:13554496981@126 com通信作者:宋恩峰(1965 03—),男,博士研究生,主任医师,研究方向:肿瘤的发病机制及中医治疗,E mail:songef@126 com临床研究健脾生血颗粒治疗类风湿关节炎并发缺铁性贫血的临床观察梅莎莎 宋恩峰 项 琼(武汉大学人民医院中医科,武汉,430060)摘要 目的:探讨健脾生血颗粒治疗类风湿关节炎并发缺铁性贫血的临床疗效及作用机制。
方法:选取2017年1月至2018年12月武汉大学人民医院中医科收治的类风湿关节炎并发缺铁性贫血的患者87例作为研究对象,随机分为观察组(n=47)和对照组(n=40)。
2组患者均口服来氟米特和甲氨蝶呤片。
对照组给予福乃得口服治疗。
观察组给予健脾生血颗粒口服。
2组连续治疗8周后观察患者的中医证候积分变化、血生化及铁蛋白指标指标变化、类风湿因子(RF)、红细胞沉降率(ESR)、C 反应蛋白(CRP)水平、基础药物治疗效果、不良反应发生情况。
结果:治疗后观察组的中医证候积、RF、ESR、CRP、总铁结合力水平均明显低于对照组(P<0 05),而RBC、Hb、MCV、MCH、MCHC、血清铁水平均明显高于对照组(P<0 05),2组药物不良反应及基础药物疗效比较差异均无统计学意义(P>0 05)。
结论:健脾生血颗粒治疗类风湿关节炎并发缺铁性贫血有显著疗效。
关键词 健脾生血颗粒;类风湿关节炎;缺铁性贫血ClinicalObservationonJianpiShengxueGranulesintheTreatmentofIron deficiencyAnemiainPatientswithRheumatoidArthritisMEIShasha,SONGEnfeng,XIANGQiong(DepartmentofTraditionalChineseMedicine,RenminHospitalofWuhanUniversity,Wuhan430060,China)Abstract Objective:ToinvestigatetheclinicaleffectsandtheactionmechanismofJianpiShengxueGranulesoniron deficiencyanemiainthepatientswithrheumatoidarthritis.Methods:Atotalof87casesofiron deficiencyanemiawithrheumatoidarthritisadmittedtoDepartmentofTraditionalChineseMedicineofRenminHospitalofWuhanUniversitywererandomlyintoatreatmentgroup(n=47)andacontrolgroup(n=40).Allpatientsweretreatedwithmethotrexateandleflunomidetablets.ThecontrolgroupwasgivenFunaideoralliquidandthetreatmentgroupwastreatedwithJianpiShengxueGranules.After8weeksofcontinuoustreat ment,thechangesofTCMsyndromescores,bloodbiochemicalandferritinindex,rheumatoidfactor(RF),erythrocytesedimentationrate(ESR),C reactiveprotein(CRP)level,andtheeffectofbasicdrugtreatmentandadversereactionswereobserved.Results:Af tertreatment,theTCMsyndromescore,RF,ESR,CRP,totalironbindinglevelinthetreatmentgroupweresignificantlylowerthanthoseinthecontrolgroup(P<0.05),whiletheRBC,Hb,MCV,MCH,MCHC,serumironweresignificantlyhigherthecontrolgroup(P<0.05).Therewasnosignificantdifferenceintheadversereactionsandcurativeeffectsofbasicdrugsbetweenthe2groups(P>0.05).Conclusion:JianpiShengxueGranuleshavegoodcurativeeffectsoniron deficiencyanemiainpatientswithrheumatoidarthritis.Keywords JianpiShengxueGranules;Rheumatoidarthritis;Iron deficiencyanemia中图分类号:R242文献标识码:Adoi:10.3969/j.issn.1673-7202.2020.15.014 类风湿关节炎(RheumatoidArthritis,RA)是一种以关节滑膜炎和关节外病变为主要表现的慢性自身免疫性疾病,其临床表现为多发对称性小关节肿胀、疼痛、僵硬、变形及活动受限[1],临床上常采用非甾体类抗炎药进行抗炎治疗。
健脾生血片的研究
白玉琴;陈信义
【期刊名称】《北京医药》
【年(卷),期】1989(000)003
【总页数】4页(P20-23)
【作者】白玉琴;陈信义
【作者单位】不详;不详
【正文语种】中文
【中图分类】R286
【相关文献】
1.健脾生血片与多糖铁复合物胶囊治疗妊娠期缺铁性贫血的临床对比研究 [J], 何丽;高江河;赵刚
2.健脾生血片与右旋糖酐铁片治疗妊娠期\r缺铁性贫血的临床对比研究 [J], 史生辉;李燕君;李生有;颜鲁青;郭红
3.健脾生血片治疗肝硬化脾功能亢进临床研究 [J], 刘黎明;冯雨薇;赵康;戴丹;胡东辉
4.健脾生血片联合琥珀酸亚铁片治疗妊娠期缺铁性贫血临床研究 [J], 石丹; 刘亚琼; 张毅; 王国华; 冯文
5.健脾生血片联合琥珀酸亚铁片治疗妊娠期缺铁性贫血临床研究 [J], 易红红
因版权原因,仅展示原文概要,查看原文内容请购买。
健脾生血片比较蛋白琥珀酸铁口服溶液治疗妊娠期贫血的临床疗效观察刘玉娥;胡亚俊;裴学军【摘要】目的:探讨健脾生血片治疗妊娠期缺铁性贫血的治疗效果,评估其临床疗效及安全性.方法:选择2014年8月至2016年1月华中科技大学同济医学院附属荆州医院就诊的妊娠期缺铁性贫血患者180例,分为对照组和观察组,各90例,对照组给予蛋白琥珀酸铁口服溶液,1支/次,2次/d;对照组给予健脾生血片,3片/次,3次/d.2组患者均连续治疗3个月.评估临床疗效、治疗前后红细胞计数(RBC)、血红蛋白(Hb)、红细胞比容(HCT)、红细胞平均体积(MCV)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)、血清铁(SI),记录所有不良反应.结果:2组治疗3个月后血生化指标RBC、Hb、HCT、MCV和铁代谢指标SF、TSAT和SI比较均有统计学意义(P <0.05),且观察组起效更快,指标在治疗1、2及3个月后均优于对照组(P<0.05);治疗3个月后观察组贫血伴随临床症状显著改善且总有效率更高(P<0.05);2组不良反应发生率比较差异无统计学意义(P>0.05).结论:健脾生血片治疗妊娠期缺铁性贫血的疗效显著,并可改善贫血临床症状且安全可靠,值得临床推广应用.%Objective:To explore the curative effect of Jianpi Shengxue tablet in the treatment of gestational iron deficiency anemia,and to evaluate the clinical curative effect and safety.Methods:A total of 180 patients with gestational iron deficiency anemia who were treated in our hospital from August 2014 to January 2016,were randomly divided into control group and observation group with 90 cases in each group.The control group was given Proteinsuccinylate Oral Solution,one drink one time,2 times/d;The observation group received Jianpi Shengxue tablet,three tablets one time,3times/d.The treatment last for continuous three months.The clinical curative effects of the two groups were evaluated.Red blood cell (RBC),hemoglobin (Hb),hematocrit (HCT),Mean Corpuscular Volume (MCV),serum ferfitin (SF),transferrin saturation (TSAT) and serum iron (SI) before treatment and after treatment were assessed and the adverse reactions were recorded.Results:After 3 months' treatment,the biochemical indicators such as RBC,Hb,HCT,MCV and Iron metabolism indexes such as SF,TSAT and SI levels in 2 groups were higher than that of pre-therapy (P < 0.05),while the observation group took effect faster (P < 0.05).The indexes were better than the control group in 1,2 and 3 months after treatment (P < 0.05);After 3 months,the symptom of anemia in observation group was significantly improved and the total effective rate was higher (P < 0.05);The adverse reactions of the observation group had no significant difference compared with the control group (P <0.05).Conclusion:There is a significant curative effect of Jianpi Shengxue tablet in the treatment of gestational iron deficiency anemia.It can improve anemia clinical symptoms with safety,which is worthy of clinical application.【期刊名称】《世界中医药》【年(卷),期】2017(012)011【总页数】4页(P2716-2719)【关键词】健脾生血片;蛋白琥珀酸铁口服溶液;妊娠期缺铁性贫血;临床疗效【作者】刘玉娥;胡亚俊;裴学军【作者单位】华中科技大学同济医学院附属荆州医院妇产科,荆州,434020;华中科技大学同济医学院附属荆州医院妇产科,荆州,434020;湖北省中药现代化工程技术研究中心,武汉,430052【正文语种】中文【中图分类】R259受妊娠期血容量平均值的增加、妊娠期早期呕吐反应、食欲不振等多方面生理因素的影响,妊娠期妇女的血红蛋白相对降低,而缺铁性贫血是其中常见的类型,占妊娠期贫血的95%左右。
健脾生血颗粒治疗婴幼儿缺铁性贫血50例临床观察目的观察健脾生血颗粒治疗婴幼儿缺铁性贫血的疗效。
方法将诊断为轻、中度缺铁性贫血的门诊患儿100例随机分为治疗组50例和对照组50例,治疗组口服健脾生血颗粒,对照组口服硫酸亚铁及维生素C,比较两组治疗总有效率。
结果两组比较,治疗组依从性更好(P<0.01),其中治疗组轻度贫血、中度贫血总有效率与对照组比较差异均有统计学意义(P<0.05)。
结论健脾生血颗粒治疗婴幼儿缺铁性贫血有较高的治疗价值。
标签:健脾生血颗粒;缺铁性贫血;婴幼儿缺铁性贫血是儿科常见病,多见于6个月~3岁的婴幼儿,患儿可有厌食、偏食、异食癖等表现,中度以上可见心悸、面色苍白、烦躁不安、智力发育迟缓等,增加感染风险。
本次研究以100例婴幼儿缺铁性贫血患者为研究对象,观察和比较健脾生血颗粒及常规营养支持治疗婴幼儿缺铁性贫血的临床疗效及不良反应,旨在评价健脾生血颗粒的有效性及安全性,为今后的工作提供指导依据,现报道如下。
1 资料与方法1.1 一般资料本次研究选取我科于2012年7月~2013年6月收治的100例婴幼儿缺铁性贫血患者,均经末梢血常规检查确诊,为轻中度缺铁性贫血。
排除标准:①原因不明的营养代谢障碍;②先心病等先天性疾病;③合并慢性胃肠道疾病。
将100例患儿随机分为例数相等的治疗组与对照组,其中治疗组男25例,女25例,年龄0.5~3岁,平均(1.5±0.5)岁,轻度贫血23例,中度贫血27例;对照组男26例,女24例,年龄0.5~3岁,平均(1.3±0.6)岁,轻度贫血22例,中度贫血28例。
两组患者的性别、年龄等一般资料比较差异无统计学意义(P>0.05),见表1。
表1 两组一般资料比较1.2 方法1.2.1 诊断标准血涂片可见红细胞缩小、中间透亮区扩大,血红蛋白<0.11 g/mL,且平均血红蛋白(MCH)<50 pg,红细胞平均体积(MCV)<80 fl,平均血红蛋白浓度(MCHC)<30%。
健脾生血颗粒治疗类风湿关节炎并发缺铁性贫血的临床观察作者:梅莎莎宋恩峰项琼来源:《世界中医药》2020年第15期摘要目的:探讨健脾生血颗粒治疗类风湿关节炎并发缺铁性贫血的临床疗效及作用机制。
方法:选取2017年1月至2018年12月武汉大学人民医院中医科收治的类风湿关节炎并发缺铁性贫血的患者87例作为研究对象,随机分为观察组(n=47)和对照组(n=40)。
2组患者均口服来氟米特和甲氨蝶呤片。
对照组给予福乃得口服治疗。
观察组给予健脾生血颗粒口服。
2组连续治疗8周后观察患者的中医证候积分变化、血生化及铁蛋白指标指标变化、类风湿因子(RF)、红细胞沉降率(ESR)、C-反应蛋白(CRP)水平、基础药物治疗效果、不良反应发生情况。
结果:治疗后观察组的中医证候积、RF、ESR、CRP、总铁结合力水平均明显低于对照组(P<0.05),而RBC、Hb、MCV、MCH、MCHC、血清铁水平均明显高于对照组(P<0.05),2组药物不良反应及基础药物疗效比较差异均无统计学意义(P>0.05)。
结论:健脾生血颗粒治疗类风湿关节炎并发缺铁性贫血有显著疗效。
关键词健脾生血颗粒;类风湿关节炎;缺铁性贫血Clinical Observation on Jianpi Shengxue Granules in the Treatment of Iron-deficiency Anemia in Patients with Rheumatoid ArthritisMEI Shasha,SONG Enfeng,XIANG Qiong(Department of Traditional Chinese Medicine,Renmin Hospital of Wuhan University,Wuhan 430060,China)Abstract Objective:To investigate the clinical effects and the action mechanism of Jianpi Shengxue Granules on iron-deficiency anemia in the patients with rheumatoid arthritis.Methods:A total of 87 cases of iron-deficiency anemia with rheumatoid arthritis admitted to Department of Traditional Chinese Medicine of Renmin Hospital of Wuhan University were randomly into a treatment group(n=47)and a control group(n=40).All patients were treated with methotrexate and leflunomide tablets.The control group was given Funaide oral liquid and the treatment group was treated with Jianpi Shengxue Granules.After 8 weeks of continuous treatment,the changes of TCM syndrome scores,blood biochemical and ferritin index,rheumatoid factor(RF),erythrocyte sedimentation rate(ESR),C-reactive protein(CRP)level,and the effect of basic drug treatment and adverse reactions were observed.Results:After treatment,the TCM syndrome score,RF,ESR,CRP,total iron binding level in the treatment group were significantly lower than those in the control group(P<0.05),while the RBC,Hb,MCV,MCH,MCHC,serum iron were significantly higher the control group(P<0.05).There was no significant difference in the adverse reactions and curative effects of basic drugs between the 2 groups(P>0.05).Conclusion:Jianpi Shengxue Granules have good curative effects on iron-deficiency anemia in patients with rheumatoid arthritis.Keywords Jianpi Shengxue Granules; Rheumatoid arthritis; Iron-deficiency anemia中图分类号:R242文献标识码:Adoi:10.3969/j.issn.1673-7202.2020.15.014类风湿关节炎(Rheumatoid Arthritis,RA)是一种以关节滑膜炎和关节外病变为主要表现的慢性自身免疫性疾病,其临床表现为多发对称性小关节肿胀、疼痛、僵硬、变形及活动受限[1],临床上常采用非甾体类抗炎药进行抗炎治疗。
d.:10.16252/ki.issn1004-0501-2019.05.17化健脾生血片对妊娠合并缺铁性贫血患者妊娠结局的影响何芳,冯小凤,徐义琴,许舒晴(滁州市第一人民医院妇产科,安徽滁州239000)!摘要】目的探索健脾生血片对妊娠合并缺铁性贫血患者妊娠结局的影响。
方法选取在我院产科门诊就诊的妊娠合并缺铁性贫血患者130例。
按照随机数表法分为观察组65例和对照组65例,观察组给予健脾生血片(健民药业集团股份有限公司,批准文号:Z10940043)饭后口服,1次3片,1天3次。
对照组用琥珀酸亚铁片(金陵药业股份有限公司,批准文号:H20010307)口服,1次1片(0.1g),l天3次。
两组均完成八周的口服药物治疗。
匹配同期正常妊娠者60例作为正常对照组。
每4周对患者的Hb进行观察,确认患者的恢复状态,对治疗无效的患者进行输液治疗或输血治疗。
对比观察组和对照组患者的疗效差异并与正常对照组比较,评价其对妊娠结局的影响。
结果观察组患者在产后出血和低体重儿的发生率方面明显低于对照组,差异有统计学意义(2<0.05)$观察组患者产褥感染、产后出血、早产、新生儿窒息、低体重儿等妊娠不良结局的发生率与正常对照组比较差异无统计学意义"2>0.05)$观察组总有效率为96.92%,明显高于对照组的90.63%,差异有统计学意义"2<0.05)$结论健脾生血片治疗妊娠合并缺铁性贫血可显著减低其妊娠不良结局的发生率,同时健脾生血片对妊娠合并缺铁性贫血患者疗效确切,不良反应轻微。
!关键词】健脾生血片(妊娠(缺铁性贫血(妊娠结局!中图分类号】R714.254[文献标志码】A【文章编号】10048501(2019)058508-05The Effect of Jianpi Shengxue Tablet on Pregnancy Outcome in Patients with Pregnancy Complicated with Iron Deficiency Anemia.He Fang,Feng Xiaqfeng,Xu Yiqic,ee al.The Fist People's Hospital o-Chuzhoo,Chuzhoo,A nhui239000,China $Abstract]Objective To explore the effect of Jianpi Shengxue Tablet on pregnancy outcome in patients with pregnancy and iron deficiency anemia.Methodt130patients with preenancy and iron deficiency anemia who were admitted tc the obstetric clinie of tie First People's Hospital of Chuzhou were selected.According tc the random numbee table method,there were65cases in the observation group and65cases in the controi group.The observation group was given Jianpi Shengxue tablets!Jianmin Pharma-ceuticd Group Co.Ltd,approval number:Z10940043)orally after meals,three tablets a time,three times a day.The control group was given ferrous succinate tablets!Jinling Pharmaceuticcl Co.Ltt,approval number:H20010307)oralle,one tablet(0.1g)a hme,[11]Schulz S,Richardt G,Laugwitz KL,er al Comparison of prasugret andbivalirudin vs clopidogrel and heparin in patients witS ST-seement elevation myocardial infarccon:Design and rationale of the Bavarian Reperfusion Alternatives Evaluation(BRAVE)4triae[J].Clio Cardi-o1,2014,37(5)&270-276.[12]Hamon M,Mehta S,Stee PG,er al Impact of transradial and transfemo-rai coronara interventions on bleeding and net adverse clinical events ia acute coronara syndromes[J].EuroIntervention,2011,7(1):91-97. [13]Pints DS,Ogbonnaya A,Sherman SA,er al Bivalirudin therapy is associated with improved clinicai and economic outcomes in ST-elevaion myocardiai infarcCon patents undergoing percutaneous coronara intee-[14]Capodanno D,Gargiulo G,Capranzano P,e:al Bivalirudin versus heparin with oe without glycoprotein Ilb/IIIa inhibitore in patients with STEMI underaoing primaiy PCI:An updated meta-analysir of10,350 patients from five randomized clinicai trials[J].Eue Heart J Acute Cae-diovaso Care,2016,5(3):253-262.[15]Costa F,Tijssen JG,Ariot t i S,er al Incrementai Value of the CRUSADE,ACUIBY,and HAS-BLED Risk Scores foe the Prediction of Hemo O hagicEaenteAtteOCoonayStentImpeantation in PatienteUn-degoingLongoOShotDuOation otDuaeAntipeateeetTheOapy[J].JAm Heart Assoc,2015,4(12):002524.vention:results from an observationai database)J].Cire Cardiovasc(收稿时间:2018-12-09) Quai Outcomes,2012,5(1):52-61.theeetimesaday.Both geoupscompoeted eightweeksofoeaomedication.60casesofnoemaopeegnancyweeematched asnoemaoconteoo group.The patients'Hb was measured ever4weeks to evaluate the patients'recover,and infusion therapy and blood transfusion therapy was peiormed on patients who were pared the efficacy of observation and controi group,and compared it with con-troi group to evaluated the effect on peanancy outcome.Res k its The incidenco of postpartum hemorrhaye and low birth weight infants in the observation group was significant lower than that in the control group(2<0.05).There is no significant diferenco in the incidenco of adverse pevnanco outcomes,including puerperal infection, postpartum hemorrhaye,premature de/very,neonatai asphyxia and low birth rate between observation and control groups(2>0.05).The total elective rate of the observation group was96.92%, which was significantly higher than that of the controi group(90.63%),and the daferenco was statisticall y significant(2<0.05). Conclusion Jianpi Shenyxue tablet can significant reduco the incidenco of adverse pevnanco outcomes in pevnanco with iron defi-cienco anemia and is elective in treating pevnanco with iron deficienco anemia,and the adverse reaction are mild.$Key worUs]Jianpi Shenyxue tablet;pevnanco;iron deficienco anemia;pegnanco outcome妊娠合并贫血将导致胎盘功能减退⑴,继而发生一系列病理生理改变,导致不良的妊娠结局[2]。
临床研究健脾生血片治疗缺铁性贫血临床效果的回顾性分析黎金庆-丛龙皎-黎牧郴2石憧娈2刘文兰3王文娟3胡乃东1(1北京中医药大学东直门医院,北京,4140;2首都医科大学附属北京朝阳医院,北京,40020;3首都医科大学中医药学院,北京,40069)摘要目的:回顾性分析健脾生血片治疗缺铁性贫血的临床效果与不良反应。
方法:选取2217年1月1日至ZOZO年3月30日北京中医药大学东直门医院通州院区门诊初诊、并首次用健脾生血片治疗的缺铁性贫血患者200例作为研究对象,比较治疗前后不同复查时间的血常规、血清铁、总铁结合力、铁蛋白结果,主观症状改善状况和不良反应。
健脾生血片用法为3片/次,3次/d,饭后口服。
结果:治疗前血红蛋白浓度为(83.58±15.84g/L("=200),治疗2周为(43.44±16.6/)g/L("=74),升高22.3%,与治疗前比较P=6.4647;治疗4周血红蛋白浓度(111.9±4.4)g/L("=47),接近正常。
治疗6周血红蛋白浓度完全正常为(H6.4±9.49)g/L("=30),治疗8周时血红蛋白浓度为(130.7±7.95)g/L("= 03);红细胞体积逐渐增大,平均红细胞血红蛋白含量逐渐升高,平均红细胞血红蛋白浓度也逐渐恢复正常。
铁代谢指标中总铁结合力逐渐下降,血清铁和铁蛋白浓度逐渐升高,与治疗前比较,治疗4周时这3个铁代谢指标均明显改善(P< 761)。
所有病例均在治疗1周內获得明显症状改善,不良反应发生率为3.3%(7/C26),主要是胃肠道刺激症状。
结论:健脾生血片是治疗缺铁性贫血的良好药物,能快速全面改善贫血症状和提升血红蛋白水平。
关键词缺铁性贫血;健脾生血片;治疗;中医中药Retrospective Analysis and Summary on Efficacy of Jianpi Shengxue Tablet in the Treatment of Iron Deficiency Anemia LI Jinqing1,CONG Lodgiao1,LI MucCen0,SHI Ceodnluan3,LIU Wenlan3,WANG Wenjuan3,HU Naiaodn1(1Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing141100,China;0Chaoyang Hospital, Capital Medical University,Bejnig100626,Chno;3School f TraOitionol Chinese Menicim,Caoitol Medical University,Beijing140666,Chino')Abstrrct Objective:To m ake n retrospective analysis and summary on the efficacy of Jianpi Shengxue Tablet iv the treatmeni of Von deficiency anemic.Methodt:A mmi of200patients with iron deficiency aqemiv who were anmitten to Tongzhog Braqch of Donczhimen Hospimi of Beijmg Universim of Chiqese Meniciqe from-January224to30October2222were sedcten ss the research oaects.Ali these patients were given meatment with Jianpi Shengxue Tablet foe the first1:1^.Reseds of aloob robtiqe exami-natmd,serum codcenmayod,mmi capacith and were comparen before and after11—06x1c S山£0^上dates. SuUjechve symptoms and adverse reactiodp were alse descriVen.Jianpi Shengxae Tablet was given orally aftes meals,3tablets each time,3times a day.Restlts:Hemoglobiv levei was83.58±15.81g/L(M土SD,n=226)before treatment,anp163.80±16.80g/ L(n=74)lter0week's treatment,with a24.3%iqcrease(P=0.0647).HemogObiv cogcenmaPog was111.9±4.4g/L(n= 47)at4th week lter treatment,which was qeas qormalim;46.0±9.49/L(n=30)at6th week with complete qormaPth and 184.8±7.95g/L(n=63)at8th ween.MCV,MCH and MCHC idcreasen grayually after treatment,Serum mmi bidind capaci-y decreasen,serum11'(^and ferritiv iqcreaseX grayuaPy,3nd were sivnificantm diVerent at the4th ween after treatment as com-paren with that before treatment(P<0.51).SuUjective symptoms were improveX-ween from smcmg treatment amogg al the cases.Te aCverse events were mainty gastrointestinal,occyrring V7/226cases(3.5%).Conclusion:JianpiTaClet is quite efective and saOe V the treatment of deficienca anemia,with rapia comprehensive improvement of anemia-relat-en symptoms and idcrease of hemoglogin and c X bloog cell parameters.KeyworOt deficiency ademia;Jianpi Shen/ae TaClet;Treatment;Trayitiogal Chidese meXiciqe and drues中图分类号:R255.5文献标识码:A doi:16.3969/Lipq•1673-7726.926-.48.410基金项目:国家自然科学基金面上项目(81774176)——补肾生血药调控JAK02TAT通路纠正造血细胞增殖-凋亡失衡改善化疗后骨髓抑制的机制研究作者简介:黎金庆(1964.4—),男,博士,副主任医师,研究方向:血液病临床技能与训练,通信作者:胡乃东(1965.11—),男,硕士,主任医师,研究方向:肿瘤介入治疗,E-maii:5309757522@缺铁性贫血是最常见的贫血类型,是铁缺乏导致血红蛋白合成不足所致,常见原因有月经过多、慢性消化道出血、偏食、长期大量喝浓茶[1],少数患者可因慢性血管内溶血引起铁从泌尿道丢失所致如阵发性睡眠性血红蛋白尿症⑵。
健脾生血颗粒治疗骨科择期手术贫血的临床观察作者:傅兰清胡亚俊郭小娟来源:《世界中医药》2017年第04期摘要目的:观察健脾生血颗粒治疗骨科择期手术患者贫血的临床疗效及安全性。
方法:将120例患者随机分为2组。
治疗组给予健脾生血颗粒治疗,对照组给予琥珀酸亚铁片治疗。
比较2组患者治疗前,治疗1周、2周、3周、4周、手术当日及术后1 d、1个月,术后2个月,术后3个月的血红蛋白及血清铁蛋白变化,评价2组术前等待时间及术后血清铁蛋白复常时间,药品不良反应和预后情况。
结果:1)2组治疗后血红蛋白水平均有显著改善(P关键词骨科术前贫血;健脾生血颗粒;琥珀酸亚铁AbstractObjective:To observe the clinical effect and safety of the treatment of Jianpi Shengxue granule in selective orthopaedic surgical patients with preoperative anaemia. Methods:A total of 120 cases were randomly divided into two groups with 60 in each. The treatment group was treated with JianpiShengxue granule, while the control group was treated with iron succinate. The levels of hemoglobin(Hb) and serum ferritin(SF) before treatment, after 1w, 2w, 3w, 4w,sugary day, and after 1 d, 1 m, 2 m, 3 m were recorded. To compare the recovery duration,adverse reactions and prognosis of the two groups. Results:After treatment, Hb levels in both groups were improved, and the treatment group was better than the control group after 2w, 3w,and 4w of treatment (PKey WordsIron deficiency anemia; JianpiShengxue Granule; Iron succinate中图分类号:R242文献标识码:Adoi:10.3969/j.issn.1673-7202.2017.04.027骨科大手术患者术前处于贫血状态非常普遍,患病率高达24%~44%,其中膝关节及髋置换的患者术前贫血发生率相对更高。
基金项目:中国人口福利基金会妇幼关爱基金———科研支撑计划项目(FY201700980417)作者简介:杨晓霞(1963 01—),女,博士,主任医师,研究方向:脑血管病、癫痫及头晕、头痛、抑郁、失眠等神经系统疾病,E mail:1063320473@qq com通信作者:李国前(1958 02—),男,博士,主任医师,研究方向:脑血管病、帕金森病、癫痫、抑郁等神经系统疾病,E mail:51328081@qq com健脾生血片治疗急性缺血性脑卒中合并缺铁性贫血患者的临床观察杨晓霞 李国前 王杰华(福建省泉州市第一医院,福州,362000)摘要 目的:研究健脾生血片治疗急性缺血性卒中合并缺铁性贫血患者的临床疗效。
方法:选取2017年3月至2018年5月福建省泉州市第一医院收治的急性缺血性卒中合并缺铁性贫血患者192例作为研究对象,随机分为观察组和对照组,每组96例。
观察组给予健脾生血片治疗,3片/次,3次/d,疗程3个月;对照组给予生血宝合剂治疗,15mL/次,3次/d,疗程3个月。
比较2组患者相关指标。
随访发病后6个月残疾率情况和发病后1年缺血性脑卒中复发率及全因死亡率。
结果:治疗后3个月,观察组贫血有效率显著高于对照组(P<0 05);观察组血清IL 1β、TNF α、CRP和hepcidin水平显著下降(P<0 05),对照组治疗后未显著下降,观察组炎性反应递质水平显著低于对照组(P<0 05);观察组RET、RBC、HGB水平均显著上升(P<0 05),对照组治疗后未显著上升,观察组血常规指标显著高于对照组(P<0 05);观察组血清铁(SI)、转铁蛋白饱和度(TS)显著升高且与对照组比较差异有统计学意义(P<0 05);2组不良反应比较差异无统计学意义(P>0 05);随访发病后6个月的残疾率,观察组显著低于对照组(P<0 05);随访发病后1年的缺血性卒中复发率,观察组显著低于对照组(P<0 05),随访后1年2组全因死亡率比较差异无统计学意义(P>0 05)。
·90·中医中药 Traditional Chinese Medicine 大 医 生 2021年 第 6卷 第 1期 2021 Vol.6 No.1健脾生血片对慢性心力衰竭合并贫血患者 铁代谢指标与炎性因子水平的影响娜荣华,于国庆(锡林郭勒盟中心医院中药房,内蒙古 锡林郭勒盟 026099)摘要:目的 探讨健脾生血片对慢性心力衰竭合并贫血患者铁代谢指标与炎性因子水平的影响。
方法 按照随机数字表法将锡林郭勒盟中心医院2019年3月至2020年8月收治的40例慢性心力衰竭合并贫血患者划分为对照组和观察组。
对照组20例患者实施抗炎、抗氧化、增强心功能、改善水钠潴留等常规治疗,观察组20例患者在对照组的基础上给予健脾生血片治疗,予以两组患者为期4周的治疗。
将两组患者治疗后临床疗效,治疗前后血清铁代谢指标与炎性因子水平进行对比。
结果 4周治疗结束后,观察组患者临床总有效率较对照组高;4周治疗结束后,两组患者血清铁(SI )、转铁蛋白饱和度(TS )、血红蛋白(Hb )水平均较治疗前升高,且观察组高于对照组,而血清白介素 -6(IL-6)、白介素 -1β(IL-1β)、肿瘤坏死因子 -α(TNF-α)水平均较治疗前降低,且观察组低于对照组(均P <0.05)。
结论 健脾生血片能够改善慢性心力衰竭合并贫血患者铁代谢指标,同时减轻炎症反应,疗效显著。
关键词:慢性心力衰竭 ; 贫血 ; 健脾生血片 ; 铁代谢 ; 血红蛋白 ; 炎性因子中图分类号:R541.61文献标识码:A文章编号:2096-2665.2021.01.0090.03作者简介:娜荣华,大学本科,副主任中药师,研究方向:中医药物研究。
通信作者:于国庆,大学本科,副主任医师,研究方向:中医对心血管疾病的诊疗。
慢性心力衰竭是一种以运动耐力下降为主要表现的持续性心力衰竭状态,患者常出现呼吸困难、乏力等症状。
贫血是心力衰竭患者不良预后的危险因素,可增加患者心脏移植、发生心血管事件甚至死亡的风险[1]。
健脾生血颗粒治疗老年人缺铁性贫血临床观察宋恩峰;张彩蝶;梅莎莎;裴学军;肖飞【摘要】目的:观察健脾生血颗粒治疗老年人缺铁性贫血的临床疗效及作用机制.方法:将80例符合缺铁性贫血的老年患者随机分为2组.对照组32例,给予福乃得口服治疗.治疗组48例,给予健脾生血颗粒口服.2组连续治疗30 d后观察有效率及RBC、Hb、MCV、MCH、MCHC、血清铁、总铁结合力指标变化.结果:治疗组临床总有效率明显高于对照组(P<0.05).2组治疗后RBC、Hb、MCV、MCH、MCHC、血清铁、总铁结合力均有显著改善,但2组治疗后指标比较无统计学意义(P>0.05).结论:健脾生血颗粒治疗老年人缺铁性贫血疗效显著,值得临床推广应用.【期刊名称】《世界中医药》【年(卷),期】2016(011)005【总页数】3页(P816-818)【关键词】健脾生血颗粒;老年人;缺铁性贫血;福乃得【作者】宋恩峰;张彩蝶;梅莎莎;裴学军;肖飞【作者单位】武汉大学人民医院中医科,武汉,430060;武汉大学人民医院中医科,武汉,430060;武汉大学人民医院中医科,武汉,430060;健民药业集团儿童药物研究院,武汉,430050;健民药业集团儿童药物研究院,武汉,430050【正文语种】中文【中图分类】R259随着我国进入老龄化社会,老年性疾病的发病率日益增多,越来越受到社会的关注。
老年贫血是老年人常见病多发病,其中又以缺铁性贫血最常见,其病因主要有铁吸收不良、铁摄入不足以及铁丢失过多等。
笔者通过长期临床观察,发现健脾生血颗粒治疗老年人缺铁性贫血(气血两虚证)疗效显著,现报道如下。
1.1 一般资料 80例患者均来源于我院2010年1月至2015年12月住院及门诊患者。
按随机数字表法随机分为2组,治疗组48例,男26例,女22例,年龄60~79岁,平均年龄(72.35±1.26)岁,病程3个月至5年,轻度贫血15例,中度贫血25例,重度贫血8例。
健脾生血片治疗COPD相关性贫血的临床观察朱林;闵捷;陈亚忠【摘要】目的:探索健脾生血片治疗慢性阻塞性肺病(COPD)相关性贫血的疗效、安全性和作用机制.方法:选取2015年3月至2015年9月四川大学华西医院和成都市天府新区人民医院收治的COPD相关性贫血患者共72例,随机分入观察组和对照组.观察组给予健脾生血片治疗,2片/次,3次/d,疗程1月;对照组给予维生素C片治疗,2片/次,3次/d,疗程1月.比较2组患者治疗前后血清IL-1β、血清TNF-α、血清CRP、血清铁调素、血清铁、转铁蛋白饱和度、铁蛋白、网织红细胞、血红蛋白、红细胞计数、夜间睡眠血氧饱和度、肺功能(FEV1%)、改良COPD患者生命质量评估问卷评分(mMRC);评估2组治疗结束时的有效率;比较2组随访3月、6月、12月时血红蛋白、肺功能、改良COPD患者生命质量评估问卷评分(mMRC)、年急性加重次数;记录2组治疗期间不良事件.结果:全部72例患者完成了第1个月的治疗,随访期间观察组2例患者退出研究,1例患者失访,对照组6例患者退出研究,2例患者失访.2组患者基线情况比较无统计学意义(P>0.05),具有可比性.观察组有效率91.7%,对照组有效率2.8%,组间比较有统计学意义(P<0.05).观察组IL-1β、血清TNF-α、血清CRP、血清铁调素水平均较对照组显著降低(P<0.05).观察组血清铁、转铁蛋白饱和度水平较对照组显著升高(P<0.05).观察组血清铁蛋白水平较对照组显著下降(P<0.05).观察组网织红细胞、血红蛋白、红细胞计数较对照组显著升高(P<0.05).观察组治疗后夜间睡眠血氧饱和度较对照组显著增高(P<0.05),但肺功能、改良COPD患者生命质量评估问卷评分(mMRC)直到随访第3月和第6月才显著改善(P<0.05).观察组年急性加重次数显著少于对照组(P<0.05).治疗期间,观察组1例患者出现轻微便秘,对照组1例患者出现轻微便秘,5例患者出现轻微腹泻,1例患者出现下尿路感染,判断与药物治疗无关,未发现其他不良事件.结论:健脾生血片治疗COPD相关性贫血安全有效,其作用机制除了提供铁元素外,还包括抑制慢性炎性反应,抑制铁调素,值得扩大样本量进一步研究.%Objective:To explore the efficacy , safety and mechanism of Jianpi Shengxue tablet in the treatment of chronic obstruc -tive pulmonary disease (COPD) related anemia.Methods:A total of 72 patients with COPD related anemia in our hospital from March 2015 to September 2015 were randomly divided into the observation group and the control group , with 36 cases in each group.The observation group was given Jianpi Shengxue tablet , three times a day and two pills at a time for a course of a month . The control group was given vitamin C tablets , 2 tablets a time, three times a day, and the treatment course was a month .The ser-um IL-1 beta, serum TNF-, serum CRP, serum hepcidin, serum iron, transferrin saturation and ferritin, reticulocytes, hemoglo-bin, red blood cell count , nocturnal sleep oxygen saturation , lung function ( FEV1%) , modified COPD patients to evaluate the quality of life questionnaire score ( mMRC) were compared before and after treatment .And the follow-up time was in the end of 3 months, 6 months and 12 months.Results:All of the 72 patients completed the treatment .During the follow-up period, 2 patients in the observation group withdrew from the study , and 1 patient was lost to visit .6 patients in the control group withdrew from the study, and 2 patients werelost.There was no significant difference in baseline between the two groups (P>0.05), which was comparable .The effective rate of the observation group was 91.7%, while the control group was 2.8%.The difference between the two groups was significant (P<0.05).The levels ofIL-1 beta, TNF-a, CRP and hepcidin in the observation group were sig-nificantly lower than those in the control group (P<0.05).The level of serum iron and transferrin in the observation group was significantly higher than that in the control group (P<0.05).But the level of serum ferritin in the observation group was signifi-cantly lower than that in the control group (P<0.05).The count of granulophilocyte , red blood cell and hemoglobin in the obser-vation group was significantly higher than that of the control group ( P<0.05 ) .The sleep oxygen saturation in the observation group was significantly higher than that in the control group (P<0.05), but the lung function and the dyspnea score (mMRC) were not significantly improved until the follow-up of third months and sixth months(P<0.05).The number of acute exacerba-tions in the observation group was significantly less than that of the control group (P<0.05).During the treatment period, 1 pa-tient in the observation group had mild constipation , while 5 cases had mild diarrhea , 1 case had lower urinary tract infection , and no other adverse events were found .Conclusion:Jianpi Shengxue tablet is effective and safe in the treatment of COPD related ane-mia.Except its iron supply , it also inhibits chronic inflammatory reaction and inhibits hepcidin .It is worth further studying the larger sample size .【期刊名称】《世界中医药》【年(卷),期】2018(013)005【总页数】5页(P1148-1151,1155)【关键词】慢性阻塞性肺疾病;贫血;健脾生血片;临床疗效【作者】朱林;闵捷;陈亚忠【作者单位】四川大学华西医院中西医结合科,成都,610041;四川大学华西医院中西医结合科,成都,610041;成都市天府新区人民医院中医科,成都,610213【正文语种】中文【中图分类】R242慢性阻塞性肺疾病(COPD)相关性贫血属于一种慢性病性贫血(Anemia of Chronic Disease,ACD),在COPD患者中患病率约10.4%~33.0%,是COPD患者急性加重、需要住院、住院时间延长、病死率增加的危险因素[1-2]。
健脾生血片治疗急性缺血性脑卒中合并缺铁性贫血患者的临床观察作者:杨晓霞李国前王杰华来源:《世界中医药》2020年第22期摘要目的:研究健脾生血片治療急性缺血性卒中合并缺铁性贫血患者的临床疗效。
方法:选取2017年3月至2018年5月福建省泉州市第一医院收治的急性缺血性卒中合并缺铁性贫血患者192例作为研究对象,随机分为观察组和对照组,每组96例。
观察组给予健脾生血片治疗,3片/次,3次/d,疗程3个月;对照组给予生血宝合剂治疗,15 mL/次,3次/d,疗程3个月。
比较2组患者相关指标。
随访发病后6个月残疾率情况和发病后1年缺血性脑卒中复发率及全因死亡率。
结果:治疗后3个月,观察组贫血有效率显著高于对照组(P<0.05);观察组血清IL-1β、TNF-α、CRP和hepcidin水平显著下降(P<0.05),对照组治疗后未显著下降,观察组炎性反应递质水平显著低于对照组(P<0.05);观察组RET、RBC、HGB水平均显著上升(P<0.05),对照组治疗后未显著上升,观察组血常规指标显著高于对照组(P<0.05);观察组血清铁(SI)、转铁蛋白饱和度(TS)显著升高且与对照组比较差异有统计学意义(P<0.05);2组不良反应比较差异无统计学意义(P>0.05);随访发病后6个月的残疾率,观察组显著低于对照组(P<0.05);随访发病后1年的缺血性卒中复发率,观察组显著低于对照组(P<0.05),随访后1年2组全因死亡率比较差异无统计学意义(P>0.05)。
结论:健脾生血片可有效治疗急性缺血性卒中合并缺铁性贫血且安全有效,值得临床用于缺血性脑卒中及贫血的治疗。
关键词健脾生血片;急性缺血性卒中;缺铁性贫血Abstract Objective:To study the clinical efficacy of Jianpi Shengxue Tablets in the treatment of patients with acute ischemic stroke and iron deficiency anemia.Methods:A total of of 192 patients with acute ischemic stroke and iron deficiency anemia admitted to Quanzhou First Hospital,Fujian between March 2017 and May 2018 were selected as the research objects and were randomly divided into an observation group and a control group,with 96 cases in each group.The observation group was given Jianpi Shengxue Tablets treatment,3 tablets/time,3 times/d,for 3 months; the control group was given Shengxuebao mixture treatment,15 mL/time,3 times/d,for 3 months.The related indexes of the 2 groups was compared.The rate of disability after 6 months of onset and the recurrence rate of ischemic stroke 1 year after onset and all-cause mortality were followed up.Results:At 3 months after treatment,the anemia of the observation group was significantly higher than that of the control group(P<0.05).The levels of serum IL-1β,TNF-α,CRP and hepcidin were significantly decreased in the observation group(P<0.05).The control group did not decrease significantly after treatment,and the inflammatory response transmitter level in observation group was significantly lower than the control group(P<0.05); the RET,RBC,and HGB levels in the observation group increased significantly(P<0.05),and the control group did not significantly increase after treatment.The blood routine index of the observation group was significantly higher than that of the control group(P<0.05); the serum iron(SI)and transferrin saturation(TS)of the observation group were significantly increased and there was significant difference with the control group(P<0.05); the difference in adverse reactions between the 2 groups was not statistically significant (P>0.05); the disability rate of the observation group was significantly lower than that of the control group 6 months after the onset of follow-up(P<0.05); the observation group was significantly lower than the control group(P<0.05).The recurrence rate of ischemic stroke 1 year after the onset of follow-up was significantly lower in the observation group than in the control group (P<0.05).There was no significant difference in all-cause mortality between the 2 groups at 1 year after the follow-up(P>0.05).Conclusion:Jianpi Shengxue Tablets can effectively treat acute ischemic stroke with iron deficiency anemia and is safe and effective.It is worthy of clinical use in the treatment of ischemic stroke and anemia.Keywords Jianpi Shengxue Tablets; Acute ischemic stroke; Iron deficiency anemia 中图分类号:R242 文献标识码:A doi:10.3969/j.issn.1673-7202.2020.22.020卒中是严重危害人类健康的3大主要疾病之一,具有高发病率、高致残率、高复发率的特点。
最新流行病学数据统计显示,卒中已成为导致我國居民残疾和死亡的主要疾病,每年我国大约有240万新发卒中患者,110万人死于卒中,1 110万卒中幸存者,而这其中,急性缺血性卒中(Acute Ischemic Stroke,AIS)占80%,是卒中的主要类型[1]。
脑卒中后遗症为临床所熟知,而脑卒中后贫血则未引起足够重视。
贫血有许多种病因,最常见的为缺铁[2]。
导致缺血性脑卒中后出现贫血的主要影响因素为IL-1β、TNF-α、C反应蛋白(CRP)和铁调素(Hepcidin)等细胞因子或炎性反应因子的表达上调,或者出现促红细胞生成素(EPO)的抵抗,造成机体的铁利用障碍,出现贫血症状。
临床治疗铁缺乏或铁利用障碍的主要手段是使用或不使用EPO,同时配合足量的口服或静脉铁剂,但这种治疗可能会进一步上调铁调素等炎性反应因子的表达,引起系统性潜在的心血管炎反应,从而增加心血管隐患或导致发生急性事件,故急性缺血性脑卒中合并缺铁性贫血症状目前临床治疗手段未有效缓解症状[3]。
除了化药外,中药在治疗贫血方面表现出很好的疗效,其中健脾生血片是治疗贫血的中西药复方制剂,属治疗贫血的国家三类新药,有研究表明,健脾生血片的作用不会造成炎性反应,并且还能抑制铁调素的高表达[4]。
因此本文探讨健脾生血片比较生血宝合剂治疗急性缺血性卒中合并缺铁性贫血患者的临床疗效,为临床治疗缺铁性贫血选择合理的中成药制剂提供依据,现将整个临床研究报道如下。
1 资料与方法1.1 一般资料选取2017年3月至2018年5月福建省泉州市第一医院收治的急性缺血性卒中合并缺铁性贫血患者192例作为研究对象,通过数字表法随机分为观察组和对照组,每组96例。
所有患者经急诊头部CT或磁共振成像(MRS)确诊为急性缺血性脑卒中合并缺铁性贫血。
观察组年龄49~78岁,平均年龄(61.2±2.7)岁;体质量指数(BMI)21~27 kg/m2,平均体质量指数(23.60±1.45)kg/m2。
对照组年龄52~79岁,平均年龄(62.9±2.2)岁;体质量指数(BMI)21~28 kg/m2,平均体质量指数(24.73±1.48)kg/m2。